knowledge -WSS

knowledge

author：focus 2025-10-01 21:34:22 - browse：5525

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

WSS

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Independent physicians launch a new lobbying group

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Eli Lilly, Pfizer, and others want in on the online prescription market

An outdated Medicare rule harms dementia patients with anxiety

Dewpoint Therapeutics lays off staff after losing partnerships

focus

knowledge

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

NIH director takes cautious approach to Biden drug pricing priority

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Medicare details structure of new drug price negotiation program

Eli Lilly’s Zepbound improved liver scarring in mid

Malaria cases in Florida and Texas: Here’s what you need to know

Independent physicians launch a new lobbying group

United colonoscopy coverage change 'may cost lives,' doctors say

Dewpoint Therapeutics lays off staff after losing partnerships

hotspot

My yearlong odyssey to get my son’s ADHD medication covered

Data don't support strong claims for Covid

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Senators tussle over abortion against the backdrop of a presidential campaign

BD to buy Edwards patient monitoring unit for $4.2 billion

Eli Lilly’s Zepbound improved liver scarring in mid

focus

focus

leisure time

leisure time